Shares of Fresenius SE & Co KGaA (FRA:FRE) have been given a consensus rating of “Buy” by the sixteen brokerages that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 1-year target price among brokerages that have issued ratings on the stock in the last year is €51.85 ($58.26).

A number of equities research analysts recently commented on the stock. Independent Research set a €48.00 ($53.93) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Friday, May 8th. JPMorgan Chase & Co. set a €66.30 ($74.49) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Tuesday, May 19th. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a research note on Friday, May 8th. Barclays set a €53.00 ($59.55) price objective on shares of Fresenius SE & Co KGaA and gave the company a “neutral” rating in a research note on Tuesday, June 2nd. Finally, Deutsche Bank set a €57.00 ($64.04) price objective on shares of Fresenius SE & Co KGaA and gave the company a “buy” rating in a research note on Monday, June 8th.

FRA FRE traded up €0.02 ($0.02) during trading hours on Friday, reaching €44.31 ($49.79). The company’s stock had a trading volume of 863,275 shares. Fresenius SE & Co KGaA has a fifty-two week low of €60.16 ($67.60) and a fifty-two week high of €80.00 ($89.89). The company’s 50-day moving average is €44.04 and its two-hundred day moving average is €42.92.

Fresenius SE & Co KGaA Company Profile

Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure.

Featured Story: Differences Between Momentum Investing and Long Term Investing

Analyst Recommendations for Fresenius SE & Co KGaA (FRA:FRE)

Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.